---
canonical_name: Ibogaine
alternate_names: Noribogaine, Iboga, Tabernanthe iboga, 12-Methoxyibogamine
canonical_topic: Ibogaine for Health & Longevity
short_topic_lc: ibogaine
creation_date: 2026-0728-1200
creator_ai_fullname: Opus 4.8
ep_keywords: Psychedelics, Dissociatives, Psychoactive Alkaloids, Plant Alkaloids, Iboga Alkaloids
---

# Ibogaine for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/28/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Noribogaine, Iboga, Tabernanthe iboga, 12-Methoxyibogamine


## Motivation

<!-- This motivation section was written only after the rest of the document was completed, so it reflects the full scope of the review. -->

Ibogaine is a naturally occurring compound found in the root bark of an African shrub, *Tabernanthe iboga*, used for centuries in West-Central African spiritual ceremonies. Outside that tradition, it draws attention for an unusual claim: a single high dose appears to interrupt addiction to opioids and other drugs, often suppressing withdrawal within hours. It produces a long, dream-like inward experience that differs from classic psychedelics, and its effects on the body and brain are wide-ranging and not fully understood.

Interest has grown alongside the opioid crisis and a search for treatments that work after conventional options fail. Recent observations in military veterans describing large, lasting drops in trauma, depression, and anxiety symptoms after a single treatment have renewed scientific attention. Yet ibogaine carries a serious heart-rhythm risk and has been linked to deaths, and it remains illegal in the United States, pushing most use to clinics abroad.

This review examines what the evidence shows about ibogaine's possible benefits for addiction, mood, and brain-injury recovery, weighed against its documented cardiac and neurological dangers, the quality of the underlying research, and the practical and legal realities of its use.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level overviews and expert discussions that introduce ibogaine's therapeutic promise, mechanisms, and risks.

<!-- A real-time search was performed across web search and the platforms of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension). Relevant content was found from Andrew Huberman (Huberman Lab, Nolan Williams episode) and Rhonda Patrick (FoundMyFitness science digest). No dedicated ibogaine content was found for Peter Attia, Chris Kresser, or Life Extension Magazine. -->

* [Dr. Nolan Williams: Psychedelics & Neurostimulation for Brain Rewiring](https://www.hubermanlab.com/episode/dr-nolan-williams-psychedelics-and-neurostimulation-for-brain-rewiring) - Andrew Huberman

This Huberman Lab episode features Stanford psychiatrist Nolan Williams, who leads the ibogaine traumatic brain injury research, discussing ibogaine's biology, history, modern use, and safety margins alongside other psychedelics.

* [Psychedelic drugs show potential in easing PTSD and TBI symptoms in military veterans](https://www.foundmyfitness.com/stories/iewikm/psychedelic_drugs_show_potential_in_easing_ptsd_and_tbi_symptoms_in_military_veterans) - Rhonda Patrick

A concise FoundMyFitness science digest summarizing observational findings that a single oral dose of ibogaine improved depression, anxiety, and PTSD (post-traumatic stress disorder) symptoms in special-operations veterans at six-month follow-up.

* [Ibogaine Therapy Information](https://psychedelics.berkeley.edu/substance/ibogaine/) - UC Berkeley Center for the Science of Psychedelics

An academic primer covering ibogaine's botanical origin, neuropharmacology, the Bwiti religious tradition, history of its anti-addiction use, and current safety and legal considerations.

* [A Possible Cure for Addiction and Traumatic Brain Injury](https://www.psychologytoday.com/us/blog/addiction-outlook/202404/a-possible-cure-for-addiction-and-traumatic-brain-injury) - Mark Gold

An expert commentary placing the recent ibogaine results in the context of addiction medicine, weighing the dramatic symptom reductions against the compound's cardiac dangers and the need for controlled trials.

* [Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets](https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html) - Sarah Williams

A Stanford Medicine research-news feature explaining the magnesium-ibogaine study in veterans with traumatic brain injury, the symptom improvements observed, and the cardiac-safety rationale for co-administering magnesium.

<!-- Only four of the five priority experts/publications could be matched to ibogaine content; the fifth slot is filled with a high-quality academic source (UC Berkeley) to reach five items. -->

*Note: Of the priority experts and publications, relevant ibogaine content was found only for Andrew Huberman and Rhonda Patrick. No dedicated ibogaine material could be found for Peter Attia, Chris Kresser, or Life Extension Magazine despite direct searches, so the fifth slot is filled with a high-quality academic source (UC Berkeley Center for the Science of Psychedelics).*


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "Ibogaine"; a dedicated article was found at https://grokipedia.com/page/Ibogaine. -->

[Ibogaine](https://grokipedia.com/page/Ibogaine)

The Grokipedia entry provides a broad reference overview of ibogaine's chemistry, pharmacology, anti-addictive use, cardiac toxicity, legal status, and the Bwiti cultural context.


## Examine

<!-- examine.com was searched directly using the browser tool for "Ibogaine"; the search returned "Sorry, there are no search results for ibogaine," confirming no dedicated article exists. -->

No Examine article exists for ibogaine. Examine.com focuses on dietary supplements and does not cover ibogaine, which is a controlled psychoactive alkaloid rather than a supplement.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "Ibogaine"; no dedicated product-testing article or review was found, consistent with ConsumerLab's focus on commercially available supplements. -->

No ConsumerLab article exists for ibogaine. ConsumerLab tests commercially available dietary supplements and does not cover ibogaine, a Schedule I controlled substance that is not legally sold as a supplement.


## Systematic Reviews

This section summarizes systematic reviews and meta-analyses of ibogaine identified through a real-time PubMed search.

* [A systematic literature review of clinical trials and therapeutic applications of ibogaine](https://pubmed.ncbi.nlm.nih.gov/35012793/) - Köck et al., 2022

This review of 24 studies covering 705 people who received ibogaine or noribogaine found evidence that ibogaine reduces withdrawal and craving in substance use disorders and may ease depressive and trauma-related symptoms, while documenting severe medical complications and two deaths within the included studies.

* [Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature](https://pubmed.ncbi.nlm.nih.gov/36263479/) - Mosca et al., 2023

A PRISMA-based review with a meta-analysis of side effects that found signals of anti-addictive efficacy, particularly for opioid detoxification, but flagged a significant risk of headache and emphasized worrying cardiotoxicity and mortality.

* [The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020)](https://pubmed.ncbi.nlm.nih.gov/34406452/) - Ona et al., 2022

This review classifies acute and long-lasting adverse events, identifying QTc prolongation (an electrical heart-rhythm delay) as the most common cardiac complication and calling for phase I trials with standardized products to define safety.

* [Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review](https://pubmed.ncbi.nlm.nih.gov/36933948/) - Sharma et al., 2023

A mixed-methods review of psychedelic treatments including ibogaine that reported positive but scarce data on abstinence, craving, and withdrawal, concluding there is not yet sufficient evidence to establish effectiveness for any specific substance use disorder.

* [Ibogaine and addiction in the animal model, a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/27244235/) - Belgers et al., 2016

A meta-analysis of 27 animal studies showing ibogaine reduces drug self-administration, especially within the first 24 hours, while documenting motor impairment and cerebellar cell loss that underline the need for close monitoring.


## Mechanism of Action

Ibogaine is unusual among psychoactive compounds because it acts on many systems at once rather than through a single dominant receptor. Its principal known actions include:

* **Multi-target receptor activity:** Ibogaine and its long-lived metabolite noribogaine bind, with low (micromolar) affinity, to NMDA receptors (a glutamate channel central to learning and memory), kappa- and mu-opioid receptors (the brain's natural pain and reward switches), sigma-2 receptors, and nicotinic acetylcholine receptors (acetylcholine being a signaling chemical for attention and muscle control).

* **Serotonin transporter blockade:** Noribogaine blocks the serotonin transporter (the protein that recycles the mood chemical serotonin), producing antidepressant-like effects that may persist for days because noribogaine clears slowly.

* **Neurotrophic signaling:** In laboratory models ibogaine raises levels of GDNF (glial cell line-derived neurotrophic factor) and BDNF (brain-derived neurotrophic factor) — growth signals that support and remodel neurons. This is a leading candidate mechanism for ibogaine's apparent ability to "reset" addictive behavior after a single dose, though competing views hold that the acute opioid- and NMDA-receptor effects, not lasting neuroplasticity, drive the withdrawal relief.

* **Dopamine modulation:** By dampening dopamine signaling in reward circuits, ibogaine is thought to blunt the reinforcing pull of addictive drugs.

The explanation for *why* one dose can have lasting effects is contested. The neurotrophic hypothesis (durable rewiring via GDNF/BDNF) competes with a pharmacological hypothesis (the metabolite noribogaine occupies opioid receptors long enough to bridge the withdrawal window). Both are supported by partial data, and neither is established.

**Key pharmacological properties:**

* **Half-life:** Ibogaine itself has a relatively short and highly variable half-life (roughly 4–7 hours), while the active metabolite noribogaine persists far longer (estimated 28–49 hours or more), remaining at clinically relevant concentrations for days.

* **Metabolism:** Ibogaine is converted to noribogaine primarily by the liver enzyme CYP2D6 (a drug-processing enzyme whose activity varies widely between people). CYP2D6 genotype strongly determines how fast ibogaine is cleared.

* **Selectivity:** Low — ibogaine is a "dirty" drug acting across many neurotransmitter systems rather than selectively.

* **Tissue distribution:** Ibogaine is highly lipophilic (fat-soluble), distributing extensively into fatty tissue, which contributes to its variable and prolonged pharmacokinetics.


## Historical Context & Evolution

* **Original use:** Iboga root bark has been used for centuries by the Bwiti spiritual tradition of Gabon and neighboring regions as a sacrament in initiation rituals and, in smaller doses, as a stimulant and appetite suppressant during hunting.

* **Introduction to the West:** Purified ibogaine was isolated in the early 20th century and was sold in France from the late 1930s as a mild stimulant (under the name Lambarène) before being withdrawn.

* **Discovery of anti-addiction effects:** In 1962, Howard Lotsof, a young American with a heroin dependence, took ibogaine recreationally and reported that his withdrawal symptoms and craving vanished. He spent decades advocating its use for addiction and obtained patents for that application, catalyzing underground and international treatment efforts.

* **Why it was considered for health optimization:** The combination of a reported single-dose interruption of addiction and the failure of conventional therapies to provide durable remission drove interest from researchers and patients seeking alternatives. Early U.S. research in the 1990s (including National Institute on Drug Abuse-supported work) was curtailed after cardiac safety concerns and a primate neurotoxicity finding emerged.

* **Evolution of scientific opinion:** Opinion has not settled. After U.S. research largely halted in the 1990s over cardiac and neurotoxicity concerns, investigation continued abroad and in observational settings, and the 2024 Stanford veterans study reintroduced ibogaine to mainstream scientific discussion by reporting large symptom reductions with no serious cardiac events when magnesium was co-administered. What changed was both the emergence of a candidate cardiac-risk mitigation strategy and renewed recognition of unmet need; the older neurotoxicity and arrhythmia findings have not been overturned, and the field remains divided on whether benefits can be obtained safely.


## Expected Benefits

A dedicated search of clinical trials, systematic reviews, and expert sources was performed to compile the benefit profile below. Each benefit is graded by the strength of supporting evidence.

### High 🟩 🟩 🟩

There are currently no ibogaine benefits supported by high-quality evidence (multiple randomized controlled trials or meta-analyses of RCTs). No benefit qualifies at this level.

### Medium 🟩 🟩

#### Reduction of Opioid Withdrawal Symptoms

Ibogaine's most consistently reported effect is the rapid suppression of opioid withdrawal, often within hours of a single dose. Multiple open-label studies, case series, and one observational cohort report marked reductions in withdrawal scores, and a systematic review of 24 studies concluded ibogaine reduces withdrawal symptoms and craving. The proposed mechanism is occupancy of opioid and NMDA receptors by ibogaine and its long-lived metabolite noribogaine. Evidence is limited by the absence of large blinded RCTs, small samples, and reliance on uncontrolled designs.

**Magnitude:** In observational and open-label data, opioid withdrawal scores (e.g., the Subjective Opiate Withdrawal Scale) typically fall sharply and significantly within 24–48 hours; one 12-month cohort reported significant acute withdrawal reduction (p = 0.015).

### Low 🟩

#### Reduced Drug Craving and Sustained Abstinence

Beyond acute withdrawal, ibogaine is reported to lower craving and support periods of abstinence from opioids, cocaine, alcohol, and other substances after one or a few treatments. A 12-month observational study of opioid-dependent individuals found significant reductions in drug-use severity scores sustained to one year, and uncontrolled cohorts report median abstinence of several months. The evidence base is observational, prone to selection bias (self-selected, motivated patients), and lacks controls.

**Magnitude:** One observational cohort reported abstinence or sustained reduced use over 12 months; uncontrolled cohort data describe median abstinence on the order of several months after a single treatment.

#### Improvement in Depression and Anxiety Symptoms

Ibogaine is associated with reductions in depression and anxiety, attributed partly to serotonin transporter blockade by noribogaine and possibly to neurotrophic signaling. An observational opioid cohort found significant reductions in Beck Depression Inventory scores at 12 months (p < 0.001), and the veterans study reported large anxiety and depression improvements. Data come from open-label and observational designs without placebo control, so expectancy effects cannot be excluded.

**Magnitude:** In the special-operations veterans cohort, depression symptoms fell by approximately 87% and anxiety by approximately 81% at one month (large effect sizes, Cohen's d > 2); an opioid cohort showed significant Beck Depression Inventory reductions at 12 months.

#### Functional Recovery After Traumatic Brain Injury ⚠️ Conflicted

A single prospective observational study (the Stanford MISTIC protocol) in 30 special-operations veterans with mostly mild traumatic brain injury reported large improvements in overall functioning and in PTSD, depression, and anxiety, sustained at one month, with magnesium co-administration and no serious cardiac events. The finding is striking but conflicted: it rests on one small, open-label, self-selected cohort without a control group, so the effect cannot yet be separated from placebo, regression to the mean, or the surrounding therapeutic setting. A conflict of interest is also relevant: the treatment was delivered at a commercial ibogaine clinic operated by Ambio Life Sciences, whose staff are co-authors on the study and have a direct financial interest in ibogaine's adoption, although Stanford reported receiving no funding from the clinic. The proposed mechanism is neurotrophic remodeling (raised GDNF/BDNF).

**Magnitude:** Reported one-month effect sizes were very large (functioning Cohen's d = 2.20; PTSD d = 2.54; depression d = 2.80; anxiety d = 2.13), corresponding to roughly an 88% reduction in PTSD symptoms in the study cohort.

### Speculative 🟨

#### Promotion of Neuroplasticity and Neuronal Remodeling

Laboratory studies show ibogaine raises GDNF and BDNF, growth signals that could in principle support neuronal repair and the "rewiring" thought to underlie durable behavior change. This is mechanistically plausible and frequently cited to explain single-dose effects, but it rests on animal and cell-culture data; no controlled human studies confirm a neuroplasticity-driven clinical benefit.

#### Treatment of Stimulant and Alcohol Use Disorders

Some case series and small cohorts suggest ibogaine may reduce use of cocaine, methamphetamine, and alcohol, not only opioids. The basis is anecdotal and uncontrolled, with no dedicated controlled trials, so any benefit for non-opioid addictions remains hypothesis-generating only.


## Benefit-Modifying Factors

* **CYP2D6 genotype:** Activity of the liver enzyme CYP2D6 (which converts ibogaine to noribogaine) varies widely between people. Poor metabolizers clear ibogaine slowly and reach higher, longer-lasting blood levels, which may alter both the intensity of effect and the balance between benefit and toxicity.

* **Baseline severity of symptoms:** The largest reported improvements occur in people with severe baseline addiction, depression, anxiety, or trauma symptoms, where there is more room for measurable change; effects in people with milder baseline burden are less characterized.

* **Baseline biomarker levels:** No validated blood biomarker has been shown to predict who benefits most, and benefit data are not stratified by any baseline laboratory value; measures such as baseline electrolytes (potassium, magnesium), liver enzymes, and the QTc interval currently function as eligibility and safety gates rather than as predictors of how much benefit a person will obtain.

* **Sex-based differences:** The major recent studies (veterans cohorts) enrolled only men, so sex-specific benefit data are essentially absent. Whether women experience comparable benefit is unknown.

* **Pre-existing health conditions:** Concurrent mood, trauma, or substance use comorbidities appear common in responders, but pre-existing conditions are more strongly characterized as risk modifiers (see Risk-Modifying Factors) than as benefit modifiers.

* **Age-related considerations:** Most participants in reported studies were working-age adults. Benefit data in older adults at the upper end of the target range are lacking, and age-related cardiac and metabolic changes may shift the risk-benefit balance unfavorably.


## Potential Risks & Side Effects

A dedicated search of drug-reference sources, toxicology reviews, and adverse-event systematic reviews was performed to compile the risk profile below.

### High 🟥 🟥 🟥

#### Cardiac Arrhythmia and QTc Prolongation

Ibogaine's most dangerous effect is delayed cardiac repolarization. By blocking hERG potassium channels (proteins that help reset the heart's electrical cycle), ibogaine prolongs the QTc interval (the time the heart takes to recharge between beats), which can trigger life-threatening arrhythmias including torsades de pointes (a chaotic, potentially fatal heart rhythm). This is the leading mechanism behind reported deaths. Risk is dose-related and amplified by pre-existing heart disease, electrolyte disturbances, and interacting drugs; noribogaine appears at least as cardiotoxic as ibogaine and persists for days.

**Magnitude:** QTc prolongation is the most frequently reported cardiac adverse event across studies; toxicology reviews link roughly 30 or more deaths over four decades primarily to cardiac arrest, with many cases involving pre-existing cardiac conditions or concurrent medications.

#### Fatal Toxicity / Death

Ibogaine has been associated with multiple deaths, most attributed to cardiac arrhythmia, sometimes compounded by seizures, respiratory complications, or concurrent drug use. Fatalities have occurred even in some individuals without documented prior cardiac disease. Because most use occurs in unregulated settings without cardiac monitoring, the true fatality rate is uncertain but clearly non-trivial relative to the small treated population.

**Magnitude:** Toxicology and systematic reviews document on the order of 30 or more ibogaine-associated deaths over approximately 40 years; within one systematic review of 24 clinical studies, two of 705 treated individuals died.

### Medium 🟥 🟥

#### Acute Cerebellar and Motor Impairment (Ataxia)

During and shortly after dosing, ibogaine commonly causes ataxia (loss of coordinated movement), unsteadiness, tremor, and difficulty walking, reflecting effects on the cerebellum (the brain's movement-coordination center). These acute effects typically resolve within 24 hours but create fall and injury risk and necessitate supervised rest.

**Magnitude:** Ataxia and motor impairment are reported in the first 24 hours in the large majority of treated individuals across clinical and observational studies; animal meta-analysis confirms consistent motor impairment in this window.

#### Acute Neuropsychiatric and Gastrointestinal Effects

The ibogaine experience includes a prolonged (often 24+ hour) dream-like, oneirogenic state with vivid visions, which can be distressing, alongside nausea, vomiting, headache, and fatigue. A meta-analysis identified a significant increased risk of headache after treatment. Severe anxiety, confusion, or transient psychiatric disturbance can occur acutely.

**Magnitude:** Headache risk was significantly elevated in a meta-analysis of side effects; nausea, vomiting, and prolonged fatigue are reported in a high proportion of treated individuals.

#### Potential Neurotoxicity (Cerebellar Cell Loss)

High doses of ibogaine cause degeneration of Purkinje cells in the cerebellum in rats, mediated by overstimulation of the inferior olive. This is a consistently reproduced preclinical finding — the animal meta-analysis of ibogaine documented cerebellar cell loss persisting for weeks after administration — which is why it is treated as a substantive safety concern rather than a fringe one. Whether it occurs at human therapeutic doses is unresolved; rodent studies found no clear neurotoxicity below about 25 mg/kg, and human neurotoxicity has not been confirmed, but the reproducibility of the animal signal and the high doses sometimes used keep it a real concern.

**Magnitude:** Cerebellar cell loss is consistently documented across animal studies at high doses (above ~25 mg/kg) and can persist for weeks; human equivalence at typical treatment doses is not established.

### Low 🟥

#### Seizures

Seizures have been reported during ibogaine treatment in a minority of cases, sometimes contributing to adverse outcomes. The mechanism is not fully defined but may relate to ibogaine's broad neurotransmitter effects and, in some cases, to withdrawal states or co-ingested substances.

**Magnitude:** Seizures appear in a minority of adverse-event case reports; precise incidence is not quantified in available controlled data.

### Speculative 🟨

#### Long-Term Psychiatric or Cognitive Effects

Because controlled long-term follow-up is scarce, the possibility of lasting psychiatric destabilization, persistent perceptual changes, or subtle cognitive effects after ibogaine cannot be excluded. The basis is isolated reports and theoretical concern from its neurotoxic potential rather than systematic long-term data.


## Risk-Modifying Factors

* **CYP2D6 genotype:** Poor metabolizers (those with low activity of the CYP2D6 enzyme, or taking CYP2D6-inhibiting drugs) clear ibogaine slowly, producing higher and more prolonged blood levels that increase the risk of QTc prolongation and arrhythmia. CYP2D6-based dosing has been proposed to improve safety.

* **Baseline cardiac status and electrolytes:** Pre-existing heart disease, structural abnormalities, long-QT tendencies, and low potassium or magnesium markedly raise arrhythmia risk. Magnesium co-administration has been used specifically to counteract QTc prolongation, and corrected electrolytes are considered protective.

* **Sex-based differences:** Women have, on average, longer baseline QTc intervals than men and a higher general susceptibility to drug-induced torsades de pointes, which could theoretically increase ibogaine's cardiac risk in women; however, the major recent studies enrolled only men, so direct sex-comparative risk data are lacking.

* **Pre-existing health conditions:** Liver impairment (altering metabolism), seizure disorders, severe psychiatric instability, and cardiovascular disease all heighten risk and are common grounds for exclusion from supervised treatment.

* **Age-related considerations:** Older adults more often have undiagnosed cardiac disease, take interacting medications, and have reduced drug clearance, all of which raise the likelihood of serious cardiac events, including at the older end of the target range.


## Key Interactions & Contraindications

* **Prescription drug interactions:** Drugs that prolong the QTc interval — certain antiarrhythmics (amiodarone, sotalol), some antipsychotics (haloperidol), macrolide antibiotics (azithromycin), and methadone — combine dangerously with ibogaine to raise arrhythmia risk. *Severity: absolute contraindication to caution; consequence: additive QTc prolongation and torsades de pointes.*

* **CYP2D6-affecting drugs:** Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) slow ibogaine clearance, raising blood levels and toxicity. *Severity: caution; consequence: elevated, prolonged ibogaine/noribogaine exposure. Mitigation: avoid co-administration or adjust dosing based on CYP2D6 status.*

* **Opioids:** Continued opioid use (including long-acting methadone) around ibogaine dosing is hazardous, both because methadone itself prolongs QTc and because of unpredictable interactions during withdrawal; supervised opioid transition or separation in timing is used. *Severity: caution to contraindication; consequence: arrhythmia and complicated withdrawal. Mitigation: timing separation and medical transition off long-acting opioids beforehand.*

* **Over-the-counter medication interactions:** Some OTC agents prolong QTc or affect CYP2D6, including certain antihistamines (diphenhydramine) and the cough suppressant dextromethorphan (a CYP2D6 substrate). *Severity: caution; consequence: additive cardiac risk or altered metabolism.*

* **Supplement interactions:** Stimulant supplements and those affecting heart rhythm or serotonin should be avoided. *Severity: caution; consequence: additive cardiac or serotonergic risk.*

* **Supplements with additive (intended) effects:** Magnesium is deliberately co-administered with ibogaine in some protocols because it can shorten or stabilize the QTc interval and may reduce arrhythmia risk; potassium repletion serves a similar protective role. *Severity: beneficial/monitored; consequence: reduced QTc prolongation.*

* **Other intervention interactions:** Combining ibogaine with other psychoactive substances (alcohol, stimulants, other psychedelics such as 5-MeO-DMT) increases unpredictability and risk and is generally separated in time when used sequentially.

* **Populations who should avoid ibogaine:** Individuals with cardiovascular disease, long-QT syndrome or QTc prolongation, recent myocardial infarction (<90 days), uncontrolled electrolyte disturbances, significant liver impairment, seizure disorders, pregnancy, or severe psychiatric instability. *Specific thresholds: baseline QTc above roughly 450 ms (men) / 470 ms (women) is commonly treated as a contraindication; recent MI (<90 days) and Child-Pugh Class C liver disease are grounds for exclusion.*


## Risk Mitigation Strategies

* **Comprehensive cardiac screening before treatment:** Obtain a baseline electrocardiogram and exclude QTc prolongation, structural heart disease, and arrhythmia history to prevent the fatal cardiac arrhythmia that is ibogaine's principal lethal risk; a baseline QTc above ~450 ms (men) / ~470 ms (women) is treated as disqualifying.

* **Continuous cardiac monitoring during dosing:** Administer ibogaine only with continuous electrocardiogram (ECG, a recording of the heart's electrical activity) and vital-sign monitoring and resuscitation capability for at least 24 hours, since QTc prolongation and torsades de pointes typically arise during this window; this directly mitigates the risk of undetected fatal arrhythmia.

* **Electrolyte optimization and magnesium co-administration:** Correct potassium and magnesium before and during treatment and co-administer magnesium (as in the MISTIC protocol) to stabilize the QTc interval, mitigating arrhythmia risk; the recent veterans study reported no serious cardiac events using this approach.

* **CYP2D6 genotyping and individualized dosing:** Test CYP2D6 status where possible and reduce dose for poor metabolizers, because slow clearance raises blood levels and cardiotoxicity; pharmacokinetic researchers recommend genotype-guided dosing to mitigate overdose toxicity.

* **Medical screening of liver, neurological, and psychiatric status:** Exclude or closely manage significant liver impairment, seizure disorders, and severe psychiatric instability before treatment to mitigate the risks of altered metabolism, seizures, and acute psychiatric decompensation.

* **Medication review and washout:** Review and discontinue or time-separate QTc-prolonging and CYP2D6-inhibiting drugs (including long-acting opioids such as methadone) before dosing, mitigating the additive arrhythmia and toxicity risks from interactions.


## Therapeutic Protocol

* **Standard supervised protocol:** Leading practitioners and the recent research protocols administer a single oral dose of ibogaine hydrochloride under continuous medical and cardiac monitoring, preceded by cardiac and laboratory screening and followed by a monitored recovery period of at least 24 hours. Pharmacokinetic research used a single dose of 10 mg/kg ibogaine hydrochloride; clinic doses vary widely.

* **Competing therapeutic approaches:** Two main models exist without one being the default. The addiction-treatment model (popularized in international and underground clinics following Howard Lotsof's advocacy) uses ibogaine to interrupt opioid withdrawal and craving. The neuropsychiatric model (developed by Nolan Williams and colleagues at Stanford in collaboration with the VETS foundation and an Ambio clinic in Mexico) pairs ibogaine with magnesium for trauma- and brain-injury-related symptoms. A purified standardized-product approach competes with traditional iboga-extract preparations.

* **Expert/clinic attribution:** Howard Lotsof popularized the anti-addiction application; the Stanford Brain Stimulation Lab under Nolan Williams developed the Magnesium-Ibogaine MISTIC protocol for traumatic brain injury.

* **Best time of day:** Dosing is typically done in the morning under supervision so that the prolonged (24+ hour) acute experience and the highest-risk cardiac window occur during staffed monitoring hours.

* **Half-life consideration:** Ibogaine has a short, variable half-life (~4–7 hours), but its active metabolite noribogaine persists for days (~28–49+ hours), so a single dose produces effects extending well beyond the acute session.

* **Single versus split dosing:** The dominant model is a single supervised dose rather than divided dosing; one alcoholism trial used an open-label escalating-dose design, but split or repeated dosing is not standard and increases cumulative cardiac exposure.

* **CYP2D6 and dose choice:** Because CYP2D6 genotype strongly governs clearance, genotype-guided dose reduction for poor metabolizers has been proposed to improve the safety of dose selection.

* **Sex-based differences in dosing:** Direct dosing data in women are lacking because key studies enrolled only men; women's longer baseline QTc warrants extra cardiac caution in dose selection.

* **Age-related considerations:** Older adults' reduced drug clearance and higher cardiac risk argue for conservative dosing and stricter screening, including at the upper end of the target range.

* **Baseline biomarkers influencing response:** Baseline electrolytes (potassium, magnesium), liver function, and ECG findings are used to determine eligibility and dose rather than to predict efficacy, given the absence of validated efficacy biomarkers.

* **Pre-existing conditions influencing response:** Severity of baseline addiction or psychiatric symptoms appears to track with larger reported improvements, while cardiac, hepatic, or seizure conditions restrict eligibility.


## Discontinuation & Cycling

* **Lifelong versus short-term:** Ibogaine is used as a one-time or occasional acute intervention, not a daily long-term medication; the model is a single supervised treatment intended to open a window for behavioral change rather than ongoing administration.

* **Withdrawal effects:** Ibogaine itself is not associated with a recognized physical dependence or withdrawal syndrome; the relevant withdrawal in practice is from the opioids or other drugs being treated, which ibogaine is used to suppress.

* **Tapering-off protocol:** Because dosing is typically a single event, no taper of ibogaine is involved; what requires careful management is the transition off pre-existing long-acting opioids (e.g., methadone) before treatment.

* **Cycling for efficacy:** Cycling is not an established practice; some clinics offer occasional repeat or "booster" sessions, but repeated dosing increases cumulative cardiac risk and is not supported by controlled evidence.

* **Relapse consideration:** Because reported abstinence often wanes over months, follow-up psychosocial support and integration are emphasized over repeat dosing to sustain benefit.


## Sourcing and Quality

* **Product forms and variability:** Ibogaine is encountered as purified ibogaine hydrochloride, semi-synthetic or total-alkaloid iboga extracts, and crude root-bark scrapings; potency and purity vary enormously between these, and adverse-event reviews specifically attribute risk heterogeneity to inconsistent products.

* **What to look for:** Where treatment is legal, standardized pharmaceutical-grade ibogaine hydrochloride with verified content and purity is strongly preferable to extracts or root bark, because known concentration is essential for safe, weight-based dosing.

* **Third-party testing and analytical verification:** Because ibogaine is unregulated in most jurisdictions, independent laboratory analysis (e.g., quantification of ibogaine content and screening for contaminants) is the only way to confirm what a product contains; the absence of regulatory oversight makes verified analytical testing especially important.

* **Reputable sources and compounding:** Standardized supply is associated with research-affiliated and licensed international clinics (such as those collaborating with academic groups) rather than informal suppliers; no FDA-approved pharmaceutical product exists in the United States.


## Practical Considerations

* **Time to effect:** Effects on withdrawal and craving are typically rapid — within hours of a single dose — and reported mood and trauma benefits in studies were evident within days and persisted to one month or longer.

* **Common pitfalls:** The most dangerous mistakes are undergoing treatment without cardiac screening or monitoring, continuing QTc-prolonging or CYP2D6-inhibiting medications, using unverified products of unknown potency, and treating in unsupervised settings without resuscitation capability.

* **Regulatory status:** In the United States ibogaine is a Schedule I controlled substance, making clinical use illegal outside specifically approved research; it is legal or unscheduled in some countries (e.g., New Zealand, where one cohort was studied) and available as a controlled or tolerated treatment in clinics in Mexico and elsewhere.

* **Cost and accessibility:** Because treatment is generally unavailable domestically in the U.S., access usually requires travel to international clinics, and supervised treatment with medical monitoring is expensive and not covered by insurance, making it difficult to access.


## Interaction with Foundational Habits

* **Sleep:** The interaction is direct and disruptive acutely — the prolonged oneirogenic (waking-dream) state and stimulant-like effects suppress and fragment sleep for the duration of the experience and sometimes for days afterward as noribogaine clears. Practically, the recovery period should allow for several days of irregular sleep, and sleep hygiene support is part of integration.

* **Nutrition:** The interaction is indirect. Nausea and vomiting are common during dosing, so treatment is typically done fasted or on a light stomach; electrolyte-rich nutrition (especially potassium and magnesium) before and after is relevant because electrolyte balance directly affects cardiac safety.

* **Exercise:** The interaction is direct in the acute phase — ataxia and motor impairment make any exertion unsafe during and immediately after dosing, requiring supervised rest. There is no evidence ibogaine blunts or enhances training adaptations; the practical consideration is avoiding physical activity until coordination and cardiac status normalize.

* **Stress management:** The interaction is potentiating in intent — the introspective experience and reported reductions in trauma, depression, and anxiety symptoms are thought to support stress recovery, and structured psychological integration and support afterward are considered important to consolidate any benefit and manage the emotionally intense experience.


## Monitoring Protocol & Defining Success

Before treatment, a thorough baseline assessment is essential given ibogaine's cardiac risk: this includes a baseline ECG for QTc, a metabolic and electrolyte panel, liver function tests, and, where available, CYP2D6 genotyping, alongside cardiac and psychiatric history.

Ongoing monitoring centers on the acute treatment window: continuous ECG and vital-sign monitoring during dosing and for at least 24 hours afterward, with electrolyte rechecks as needed, followed by clinical and psychological follow-up in the weeks after treatment (e.g., at 1 week, 1 month, then periodically) to track symptom change and integration.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --------- | ------------------------ | --------------- | ------------- |
| QTc interval (ECG) | < 440 ms (men), < 450 ms (women) | Detects the heart-rhythm delay that drives ibogaine's fatal arrhythmia risk | Conventional upper limits are higher (~450/470 ms); a tighter functional target is safer. Continuous monitoring during and ≥24 h after dosing |
| Serum potassium | 4.0–4.5 mmol/L | Low potassium worsens QTc prolongation and arrhythmia risk | Conventional range (3.5–5.0) is wider; keep toward the upper-middle. Correct before dosing |
| Serum magnesium | High-normal (≥ 0.9 mmol/L) | Magnesium stabilizes cardiac rhythm and is co-administered to protect against QTc prolongation | Repletion is part of the MISTIC protocol; recheck during treatment |
| Liver enzymes (ALT/AST) | ALT/AST < 25 U/L | Ibogaine is metabolized hepatically; impairment raises exposure and toxicity | Conventional "normal" extends to ~40 U/L; lower functional target preferred. Fasting sample |
| CYP2D6 genotype | Normal (extensive) metabolizer | Poor metabolizers clear ibogaine slowly, raising toxic exposure | One-time genetic test; guides dose reduction if poor metabolizer |

Qualitative markers of success and safety include:

* Resolution or marked reduction of opioid withdrawal symptoms within 24–48 hours
* Reduced craving and self-reported drug use over weeks to months
* Improvements in mood, anxiety, sleep, and overall daily functioning
* Absence of cardiac symptoms (palpitations, fainting, chest discomfort) during and after treatment


## Emerging Research

* **Stanford Magnesium-Ibogaine traumatic brain injury (TBI) trial (MISTIC):** The observational study underpinning recent interest is registered as [NCT04313712](https://clinicaltrials.gov/study/NCT04313712) (Stanford University; ~30 participants; veterans with blast exposure and head injury; primary outcome WHODAS 2.0, the World Health Organization Disability Assessment Schedule, a standardized measure of overall functioning), with results published by [Cherian et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38182784/); controlled trials are needed to confirm the open-label findings.

* **Oral ibogaine for opioid withdrawal (atai):** A completed Phase 1/2 study, [NCT05029401](https://clinicaltrials.gov/study/NCT05029401) (atai Therapeutics; ~116 participants; opiate withdrawal syndrome; primary outcome short opioid withdrawal scale), is among the larger formal trials of a standardized oral ibogaine product and could strengthen the safety/efficacy evidence base. The sponsor, atai Therapeutics, is a commercial drug developer with a direct financial interest in ibogaine's approval, which is relevant to weighing how its trial results are framed.

* **Neuroimaging of ibogaine in opioid use disorder:** A recruiting study, [NCT07226570](https://clinicaltrials.gov/study/NCT07226570) (University of California, Irvine; ~20 participants; opioid use disorder; primary outcomes include resting-state connectivity and nucleus-accumbens glutamate), aims to clarify the brain mechanisms behind ibogaine's anti-addictive effects.

* **Ibogaine in alcohol use disorder:** A completed Phase 2 open-label escalating-dose trial, [NCT03380728](https://clinicaltrials.gov/study/NCT03380728) (University of Sao Paulo; ~9 participants; alcoholism; primary outcome time without alcohol use), explores whether benefits extend beyond opioids.

* **Pharmacokinetics and CYP2D6-guided dosing:** Work by [Knuijver et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38519421/) showing ibogaine clearance is strongly tied to CYP2D6 genotype points toward individualized dosing as a future direction that could weaken or strengthen the safety case depending on whether genotype-guided dosing reliably reduces cardiac events.

* **Safer iboga-derived analogues:** Research on non-cardiotoxic congeners — for example oxa-iboga alkaloids reported by [Havel et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39304653/) and the long-studied 18-methoxycoronaridine — represents a future direction that could either supersede ibogaine (if analogues retain benefit without cardiac risk) or, if they fail, reinforce ibogaine's niche.


## Conclusion

Ibogaine is a plant-derived compound best known for an unusual property: a single dose appears to interrupt drug withdrawal and craving and, in early studies, to ease depression, anxiety, and trauma symptoms, including in people recovering from brain injury. These reported effects are large and rapid, and they have revived serious scientific interest after decades on the margins.

The evidence, however, is still weak. Almost all human findings come from small, uncontrolled, or observational studies in people who chose the treatment themselves, leaving the reported benefits intertwined with expectation and the surrounding care. Some of the most influential results also carry a conflict of interest, having come from commercial ibogaine clinics and a drug company that stand to gain from the compound's adoption. Against this sits a clear and serious danger: ibogaine can disturb the heart's rhythm in ways that have been linked to deaths, and it can cause coordination problems, seizures, and possible brain effects. Pairing it with magnesium and close heart monitoring appears to lower the cardiac risk, though that protection remains uncertain.

Ibogaine is illegal in the United States and mostly available only through clinics abroad, at high cost. What emerges is a compound with striking but unproven promise alongside real, sometimes fatal, hazards: the reported effects are large, while the evidence supporting them remains early-stage and uncertain.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**

<section id="iterations" markdown="1"></section>